RGNX · REGENXBIO Inc.
$7.76
+0.33 (+4.44%)
At close · Oct 5
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing no longer states the doubt (first flagged May 14, 2026).
View the 10-Q filed Aug 6, 2026Market Cap
$488.50M
Shares
66.01M
Volume · Oct 5
2.35M
Avg daily vol (3M)
1.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.76
Open$7.80
Day$7.57–8.16
52W close$5.65–15.98
Avg vol 30d1.5M
Short int7.9M · 12.0% float · 7.7d
Short vol67%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$174.48M
Trailing 12 months
Net income (TTM)
−$196.43M
Trailing 12 months
Revenue growth YoY
+405.7%
Year over year
Operating margin
-94.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-51.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$105.52M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.0%
Year over year · more shares
Price change (1Y)
-29.8%
Trailing year
Short interest
12.0%
Latest settlement · 7.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−21%
below
Price vs 50-day avg
−16%
below
RSI (14)
42
neutral
MACD trend
Positive
52-week position
20%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−13%
trailing
6-month return
−17%
trailing
YTD return
−46%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Flat
2 of 168 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$949.4K over 90 days · 0% sells
Short interest
Rising
12.01% of float · ▲ +5.7% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
168 holders — mid 3-yr range
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+126%
Y/Y
EPS growth
+18%
Y/Y
Free cash flow
$-126.4M
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−65%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Nov 8, 2023
Total savings
· over the next two years
at least $100M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−21%
Bearish
Price vs 50-day avg
−16%
Bearish
RSI (14)
42
Neutral
MACD trend
Positive
Bullish
52-week position
20%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $9 › 200d $10 — 200d above 50d
Institutional flow
Flat
2 of 168 funds reported for Sep 30 · net 0 sh shares
Insider flow
Accumulating
Net +$949.4K over 90 days · 0% sells
Short interest
Rising
12.01% of float · ▲ +5.7% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
168 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $8 · 20%
Range high $16
vs 200-day avg -21%
vs 50-day avg -16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Interest income from licensing | $10K | Three Months Ended June 30, 2026 filing | — |
| Itvisma royalties | $2.09M | Three Months Ended June 30, 2026 filing | — |
|
|
|||
| License and royalty revenue under AbbVie Collaboration Agreement | $100M | Three Months Ended June 30, 2026 filing | — |
| Net cost reimbursement to (from) AbbVie included in General and administrative expense | $1.23M | Three Months Ended June 30, 2026 filing | — |
| Net cost reimbursement to (from) AbbVie included in Research and development expense | -$12.05M | Three Months Ended June 30, 2026 filing | — |
| Total net cost reimbursement to (from) AbbVie | -$10.82M | Three Months Ended June 30, 2026 filing | — |
| Zolgensma royalties | $1.75M | Three Months Ended June 30, 2026 filing | -90.5% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RGNX
this stock
REGENXBIO Inc.
|
$488.50M | -46.1% | +126.5% | — | 12.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RGNX | +3.9% | -13.2% | -16.6% | +3.1% | -46.1% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +2.7% | -13.8% | -28.1% | +1.5% | -59.7% |